Loading…
← CockpitCompetitor Analysis › 301207.SZ Hualan Biological Vaccine Inc. Class AOpen in the cockpit ↗

Hualan Biological Vaccine Inc. Class A301207.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Vaccine subsidiary of Hualan Biological Engineering, making influenza and other vaccines for the domestic market.

Momentum weak 24
Mkt cap
$1.25B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$17.8M
20-day average traded
Fwd P/E
38.6×
forward earnings
ROIC−WACC
-8.7 pp
WACC 10.1%
Hurdle
+46 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥14.20
1D+1.1%
1W-6.3%
1M-24.9%
3M-21.8%
6M-28.5%
YTD-23.8%
1Y-39.8%
ATR %5.2%
52w lowhigh49.1% off high

What Hualan Biological Vaccine does

Vaccine subsidiary of Hualan Biological Engineering, making influenza and other vaccines for the domestic market.

Influenza shots in China are mostly category-two vaccines, paid for by individuals rather than the state programme, so sales depend on seasonal uptake and on provincial disease-control centers' procurement. The season is brief, so sales concentrate in the autumn. Its parent, Hualan Biological Engineering, lists separately.

Products and services

  • Influenza vaccines
  • Other pediatric vaccines

Customers

  • CDC/vaccination centers
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

What could go right

  • Flu vaccination uptake growth

What could go wrong

  • Vaccine procurement price pressure
  • Seasonal demand volatility

Moat: narrow (regulatory licence, distribution). Leverages parent Hualan's plasma/vaccine manufacturing scale and distribution network.

Headquarters: Xinxiang, China · Employees: 708

Named competitors

Hualan Biological Vaccine at a glance

Size Hualan Biological Vaccine (301207.SZ) is a China Health Care company (Biotechnology) with a market value of $1.25B, the 1781st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.20 on 18 Nov 2026.

Performance Over six months the shares fell 28.5%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 28.4% over the last twelve months (peer median +15.8%); the operating margin is -7.4% (peer median -178.1%).

Valuation It trades at 38.6× forward earnings against a peer median of 44.0× (4th cheapest of 8).

Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +46 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.7 points below its cost of capital (10.1% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 79301207.SZ 71
Six months, rebased to 100: Hualan Biological Vaccine against the median of its 20 peers (local-currency closes).

Hualan Biological Vaccine financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥697MCN¥1.20BCN¥1.12BCN¥2.40BCN¥1.82B
Revenue growth—+7%-53%+32%—
Gross profitCN¥529MCN¥894MCN¥868MCN¥2.07BCN¥1.55B
EBITDAn/aCN¥232MCN¥237MCN¥1.03BCN¥646M
Net incomeCN¥46.2MCN¥183MCN¥206MCN¥860MCN¥520M
Free cash flowCN¥486MCN¥491MCN¥502MCN¥878MCN¥244M
Capital expenditureCN¥20.5MCN¥9.70MCN¥51.6MCN¥62.6MCN¥92.6M
Total debtCN¥19.6MCN¥8.49MCN¥300MCN¥300MCN¥315M

Quarterly statements and history in the cockpit →

Hualan Biological Vaccine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%000403688739MLYSAKUMSNVAXNUVBGENBTYRACMPS4588ANABABSI688105301207.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hualan Biological Vaccine is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×50×100×000403688739AKUMSNVAX6185ANAB688105301207.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hualan Biological Vaccine is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688739AKUMSANAB688105301207.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hualan Biological Vaccine is the large dot.

Hualan Biological Vaccine competitors and peer comparison

Head to head with its named competitors (301207.SZ vs 300122.SZ vs 300142.SZ vs 300601.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hualan Biological Vaccine 301207.SZ$1.25B-29%-28%-7%38.6×33.2%
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%n/a-6.5%
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%348.7×29.5%
Shenzhen Kangtai Biological Products 300601.SZ$1.86B-20%-9%6%105.5×22.7%

How Hualan Biological Vaccine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hualan Biological Vaccine against its 20 peers (data as of 18 Nov 2026)
Measure301207.SZPeer medianRank in peer set
1-month return-24.9%-13.4%4th lowest of 21
6-month return-28.5%-20.3%4th lowest of 19
Distance from 52-week high-49.1%-48.0%10th lowest of 21
Revenue growth (TTM)-28.4%+15.8%3rd lowest of 16
Operating margin-7.4%-178.1%7th highest of 17
Forward P/E38.6×44.0×4th cheapest of 8
Growth the price implies (Req g, 7 yrs)33.2%11.0%2nd most demanding of 5
Growth delivered (Del g)-13.1%+3.7%lowest of 5
Hurdle (Req g minus delivered)+46.3 pp+9.5 ppmost demanding of 5
ROIC minus cost of capital-8.7 pp-6.9 pp5th lowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%26.5×n/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%44.0×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%25.6×15.3%+9.9%
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%

Questions

Who are Hualan Biological Vaccine's main competitors?
Named competitors: Chongqing Zhifei Biological Products (300122.SZ), Walvax Biotechnology (300142.SZ), Shenzhen Kangtai Biological Products (300601.SZ). The cockpit's measured peer set (industry) also includes Pacific Shuanglin Bio-pharmacy (000403.SZ), Liaoning Chengda Biotechnology (688739.SS), Mineralys Therapeutics (MLYS), Akums Drugs and Pharmaceuticals (AKUMS.NS), Taysha Gene Therapies (TSHA), Novavax (NVAX).
Is Hualan Biological Vaccine expensive compared with its peers?
On forward p/e it trades at 38.6× against a peer median of 44.0×, 4th cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +46 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hualan Biological Vaccine stock performed?
Over six months to 18 Nov 2026 the shares returned -28.5% against -20.3% for the median peer; over one year -39.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.